Evidence map›Paper›PMID 34349116›Full record

Trial reportTranslational psychiatry2021

Antidepressant side effects and their impact on treatment outcome in people with major depressive disorder: an iSPOT-D report.

Taylor A Braund, Gabriel Tillman, Donna M Palmer, Evian Gordon, A John Rush, Anthony W F Harris

Open access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Translational psychiatry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed, 5 pooled it
12.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

64 citing papers in PubMed, 5 syntheses or guidelines pooled it, 119 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Efficacy and safety of zuranolone co-initiated with an antidepressant in adults with major depressive disorder: results from the phase 3 CORAL study.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024
    Trial
  10. Effect of vitamin D supplementation on depression in older Australian adults.International journal of geriatric psychiatry · 2023
    Trial
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Observational

4 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 3 countries.

Taylor A BraundBrain Dynamics Centre, The Westmead Institute for Medical Research, Sydney, NSW, Australia. taylor.braund@sydney.edu.au.ORCID 0000-0001-8408-9070
Gabriel TillmanSchool of Science, Psychology and Sport, Federation University, Ballarat, VIC, Australia.
Donna M PalmerBrain Dynamics Centre, The Westmead Institute for Medical Research, Sydney, NSW, Australia.
Evian GordonTotal Brain, San Francisco, CA, USA.
A John RushDepartment of Psychiatry & Behavioral Sciences, Duke University, School of Medicine, Durham, NC, USA.
Anthony W F HarrisBrain Dynamics Centre, The Westmead Institute for Medical Research, Sydney, NSW, Australia.ORCID 0000-0002-8617-4962
The University of Sydney · AUFederation University · AUTexas Tech University · USTotal (United States) · USWestmead Institute for Medical Research · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Side effects to antidepressant medications are common and can impact the prognosis of successful treatment outcome in people with major depressive disorder (MDD). However, few studies have investigated the severity of side effects over the course of treatment and their association with treatment outcome. Here we assessed the severity of side effects and the impact of treatment type and anxiety symptoms over the course of treatment, as well as whether side effects were associated with treatment outcome. Participants were N = 1008 adults with a current diagnosis of single-episode or recurrent, nonpsychotic MDD. Participants were randomised to receive escitalopram, sertraline, or venlafaxine-extended release with equal probability and reassessed at 8 weeks regarding Hamilton Rating Scale Depression (HRSD

Indexed as

Major Depressive DisorderAdultAntidepressive AgentsCitalopramHumansSertralineTreatment OutcomeAntidepressive AgentsCitalopramSertraline

Identifiers

PMID34349116
PMCPMC8338944
OpenAlexW3191823183

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.